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G-protein-coupled receptors are hyper-phosphorylated in a
process that controls receptor coupling to downstream signal-
ing pathways. The pattern of receptor phosphorylation has
been proposed to generate a “bar code” that can be varied in a
tissue-specific manner to direct physiologically relevant recep-
tor signaling. If such a mechanism existed, receptors would be
expected to be phosphorylated in a cell/tissue-specific manner.
Using tryptic phosphopeptide maps, mass spectrometry, and
phospho-specific antibodies, it was determined here that the
prototypical Gq/11-coupled M3-muscarinic receptor was in-
deed differentially phosphorylated in various cell and tissue
types supporting a role for differential receptor phosphoryla-
tion in directing tissue-specific signaling. Furthermore, the
phosphorylation profile of the M3-muscarinic receptor was
also dependent on the stimulus. Full and partial agonists to the
M3-muscarinic receptor were observed to direct phosphoryla-
tion preferentially to specific sites. This hitherto unappreci-
ated property of ligands raises the possibility that one mecha-
nism underlying ligand bias/functional selectivity, a process
where ligands direct receptors to preferred signaling pathways,
may be centered on the capacity of ligands to promote recep-
tor phosphorylation at specific sites.
Agonist occupation of G-protein-coupled receptors (GPCRs)3
results in rapid receptor phosphorylation in a process that not
only mediates the uncoupling of the receptor from its cognate
G-protein but also drives G-protein-independent receptor
signaling (1–3). It is now clear that GPCR phosphorylation is
a complex regulatory mechanism involving an array of differ-
ent protein kinases that include second messenger regulated
kinases, members of the G-protein-coupled receptor kinase
(GRK) family, as well as receptor tyrosine kinases and protein
kinase CK2 and CK1 (2–4). The consequence of this kinase
activity is the hyperphosphorylation of GPCRs at sites largely
within the third intracellular loop and C-terminal tail, which
in turn promotes the recruitment of arrestin proteins that
mediate G-protein-independent signaling (1–4).
The complexity of GPCR phosphorylation allows for the
possibility that receptors might be phosphorylated differen-
tially in different cell types (5) and thereby provide a mecha-
nism by which the same receptor subtype would have differ-
ent signaling properties depending on the cell type in which
the receptor is expressed (3). This notion has been supported
by recent studies on the 2-adrenergic receptor and CXC4R
receptor where receptor phosphorylation by different mem-
bers of the GRK family can mediate different signaling out-
comes (6, 7). Furthermore, our own studies and the studies of
others on the M3-muscarinic receptor have demonstrated
that phosphorylation of this receptor subtype by CK1 regu-
lates receptor signaling to the phospholipase C and ERK path-
ways (8, 9), whereas phosphorylation mediated by protein
kinase CK2 has no impact on ERK/phospholipase C but
rather regulates the coupling of the receptor to the JNK path-
way (5).
These studies suggest that one mechanism by which re-
ceptors might direct signaling to one pathway (i.e. JNK) in
preference to another (i.e. ERK) might be via specific phos-
phorylation profiles of the receptor. By adopting a specific
phosphorylation profile or “phosphorylation signature,” a re-
ceptor could favor coupling to a particular pathway. In this
way, the phosphorylation profile of a receptor could act as a
“bar code” that encodes a particular signaling outcome (3,
10–12). Hence, in each tissue type a GPCR might adopt a dif-
ferent phosphorylation profile, or bar code, and this would
contribute to tissue-specific signaling related to the physio-
logical function of the receptor.
If such a regulatory mechanism existed, then it would be
expected that receptors would be differentially phosphory-
lated in different cell types. We test this possibility in this
study and present evidence that the M3-muscarinic receptor
is indeed differently phosphorylated in different cell and tis-
sue types. Furthermore, we show that ligands can favor spe-
cific phosphorylation events that raise the possibility of li-
gand-specific phosphorylation and thereby a mechanism by
which biased ligands could direct the preferential coupling of
receptors to downstream signaling networks.
EXPERIMENTAL PROCEDURES
Materials—Unless otherwise stated, all biochemicals and
reagents were from Sigma or from previously identified
sources (5). Radioisotope [32P]orthophosphate (specific activ-
ity 8500–9120 Ci/mmol),myo-[3H]inositol (specific activity
25 Ci/mmol), and N-[3H]methylscopolamine (specific activity
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83 Ci/mmol) were from PerkinElmer Life Sciences. The anti-
muscarinic receptor antibodies used in this study were gener-
ated in-house against a glutathione S-transferase (GST) bacte-
rial fusion protein containing the full third intracellular loop
of the mouse M3-muscarinic receptor (Arg252–Thr491).
Where rabbit polyclonal antibodies were raised, the antibod-
ies were first passed through a GST-affinity column to re-
move antibodies to GST and then purified by affinity chroma-
tography on a column containing the receptor-fusion protein.
In the case of mouse monoclonal antibodies, affinity purifica-
tion against the antigen was carried out.
Phosphorylation-specific antibodies, anti-phosphoserine
384, 412, and 577, were raised against peptide sequences
NSTKLPpSSDNLQ, HKLQAQKpSMDDRD, and YQQRQpS-
VIFHK, corresponding to amino acid residues 378–389, 405–
418, and 572–583 of the mouse M3-muscarinic receptor in
which serines 384, 412, and 577 were phosphorylated. The
87-day programs, which included four immunizations, were
performed by Eurogentec. The resulting antisera were puri-
fied against the immunizing peptides.
Generation of GST Fusion Constructs—Mouse M3-musca-
rinic receptor third intracellular loop Arg252 to Thr491 and the
C-terminal Lys548 to Leu589 were inserted into pGEX-2t to
produce N-terminal GST fusions. Escherichia coli BL21 (DE3)
IRL transformed with the fusion constructs or pGEX-2t alone
was grown in LB medium containing 50 g/ml ampicillin, 50
g/ml chloramphenicol, and 1% w/v glucose; protein expres-
sion was induced by addition of isopropyl 1-thio--D-galacto-
pyranoside to a final concentration of 200 M.
Culture of CHO-M3 Wild-type Stable Cell Lines—CHO cells
stably expressing the wild-type M3-muscarinic receptor were
maintained in Ham’s F-12 medium (Invitrogen) supple-
mented with 10% fetal calf serum (FCS), penicillin (50 units/
ml), streptomycin (50g/ml), and geneticin G418 (500g/ml).
Experiments were performed in Krebs/HEPES buffer
(118 mM NaCl, 1.3 mM CaCl2, 4.3 mM KCl, 1.17 MgSO4,
4.17 mM NaHCO3, 1.18 mM KH2PO4, 11.7 mM glucose, 10
mM HEPES (pH 7.4)) or in a modified Krebs/HEPES buffer
as indicated.
Preparation and Primary Culture of Mouse Cerebellar
Granule Neurons—Mouse CG neurons were prepared and
cultured as described previously (5), trypsin- dissociated, and
plated on poly-D-lysine-coated 6-well plates at a density of
2 106 cells well. The neurons were maintained in Eagle’s
basal medium (Invitrogen) supplemented with 20 mM KCl,
penicillin/streptomycin, and 10% FCS. After 48 h, cytosine
arabinoside (10 M) was added to prevent glial cell prolifera-
tion, and the culture was continued for 7–8 days. Experi-
ments were then performed on cells that were washed and
then maintained in CSS-25 buffer (120 mM NaCl, 1.8 mM
CaCl2, 25 mM KCl, 15 mM glucose, 25 mM HEPES (pH 7.4)).
M3-muscarinic Receptor Purification and Mass
Spectrometry—For the mass spectrometry experiments, a sta-
bly transfected CHO cell line was generated that expressed a
mouse M3-muscarinic receptor HA-tagged at the C terminus.
For receptor purification, 20 confluent T175 flasks were har-
vested and resuspended in 40 ml of Krebs/HEPES buffer and
stimulated with methacholine (100 M, 5 min). Membranes
were then prepared and solubilized by addition of 5 ml of PBS
containing 1% Nonidet P-40 plus a mixture of protease and
phosphatase inhibitors. After centrifugation at 20,000 g, the
resulting supernatant was diluted 1:1 with PBS, and the recep-
tor was then purified on anti-HA affinity resin (Roche Diag-
nostics). After extensive washing with solubilization buffer
containing 0.5% Nonidet P-40, the resin was resuspended in
2 SDS-PAGE sample buffer. The sample was resolved by
SDS-PAGE on 8% gels and stained with colloidal Coomassie
Blue. Purified M3-muscarinic receptors were excised from the
polyacrylamide and washed three times for 15 min with 100
mM ammonium bicarbonate. Reduction and alkylation of cys-
teines were performed by addition of 10 mM dithiothreitol
(DTT) in 50 mM ammonium bicarbonate at 60 °C for 30 min
followed by addition 100 mM iodoacetamide in 50 mM ammo-
nium bicarbonate for 30 min in the dark. Gel slices were
washed three times for 5 min with 50 mM ammonium bicar-
bonate containing 50% acetonitrile and incubated overnight
at 37 °C in 50 mM ammonium bicarbonate containing 1 g of
sequencing grade trypsin (Promega).
LC-MS/MS was carried out on each sample using a 4000
Q-Trap mass spectrometer (Applied Biosystems, Warrington,
UK). Peptides resulting from in-gel digestion were loaded at a
high flow rate onto a reverse-phase trapping column (0.3 mm
inner diameter 1 mm), containing 5 m of C18 300 Å Ac-
claim PepMap media (Dionex, UK) and eluted through a re-
verse-phase capillary column (75 m inner diameter 150
mm) containing Symmetry C18 100 Å media (Waters) that
was self-packed using a high pressure packing device
(Proxeon Biosystems, Odense, Denmark). The output from
the column was sprayed directly into the nanospray ion
source of the 4000 Q-Trap mass spectrometer. Additional
mass spectrometry experiments were performed on an LTQ
Orbitrap mass spectrometer by “FingerPrints” Proteomics
Facility (College of Life Sciences, University of Dundee).
The resulting spectra were searched against the Uni-
ProtKB/SwissProt data base using MASCOT software (Matrix
Science Ltd.) with peptide tolerance set to 5 ppm for LTQ
OrbiTrap data or 0.1 Da for 4000 Q-Trap data, and the
MS/MS tolerance was set to 0.6 Da. Fixed modifications were
set as carbamidomethyl cysteine with variable modifications
of phosphoserine, phosphothreonine, phosphotyrosine, and
oxidized methionine. The enzyme was set to trypsin/P, and
up to two missed cleavages were allowed. Peptides with a
Mascot score greater than 20 and where the probability (p)
that the observed match was a random event was0.05 were
included in the analysis. The spectra of peptides reported as
being phosphorylated were interrogated manually to confirm
the precise sites of phosphorylation.
[32P]Orthophosphate Labeling and M3-muscarinic Receptor
Immunoprecipitation—In vivo [32P]orthophosphate labeling,
receptor solubilization, and immunoprecipitation were con-
ducted as described previously (5). In brief, CHO cells stably
expressing the human M3-muscarinic receptor were grown in
6-well plates, washed, and incubated for 1 h in KH2PO4-free
Krebs buffer containing 100 Ci/ml [32P]orthophosphate
(PerkinElmer Life Sciences). Cells were then stimulated with
0.1 mM methacholine for 5 min and lysed in RIPA buffer (2
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mM EDTA, 20 mM -glycerophosphate, 160 mM NaCl, 1%
Nonidet P-40, 0.5% deoxycholate, 10 mM Tris (pH 7.4)). M3-
muscarinic receptors were immunoprecipitated using an in-
house anti-M3-muscarinic receptor polyclonal antibody (5).
Immunoprecipitated proteins were resolved by SDS-PAGE on
8% gels, transferred to nitrocellulose membrane, and visual-
ized by autoradiography. The membrane was subsequently
blocked and immunoblotted with another in-house anti-
mouse M3-muscarinic receptor monoclonal antibody for the
detection of total receptors. To dephosphorylate the immuno-
precipitated receptor, the immune complexes were washed
three times with 10 mM Tris (pH 7.4) containing 0.25% n-
octyl glucoside before treatment with calf intestinal phospha-
tase (20 units per reaction) for 2 h at 37 °C. Receptors were
then resolved by SDS-PAGE on 8% gels and immunoblotted
with phosphorylation-specific antibodies.
For phosphopeptide mapping, CHO-M3 cells were labeled
with 100 Ci/ml of [32P]orthophosphate. Stimulation and
immunoprecipitation were carried out as described above.
The immunoprecipitated samples of one entire 6-well plate of
CHO cells were pooled and resolved by SDS-PAGE on 8%
gels. Tryptic phosphopeptide maps were prepared as de-
scribed previously (5). The resolved phosphopeptides were
then visualized using a STORM 820 phosphorimager (GE
Healthcare) and quantified using AlphaEaseFC software
(Alpha Innotech).
M3-muscarinic Receptor Immunoprecipitation from Tissue
Samples—To establish the phosphorylation status of M3-
muscarinic receptors in preparations from the hippocampus,
cerebral cortex, and whole pancreas, tissues from adult wild-
type or adult M3-muscarinic receptor knock-out mice on a
mixed genetic background (129/SvEv CF1) (25) were ex-
tracted into ice-cold HIB buffer (25 mM HEPES (pH 7.4), 120
mM NaCl, 5 mM KCl, 9.1 mM glucose) containing protease
inhibitors and phosphatase inhibitors (Complete EDTA-free,
PhosStop, Roche Diagnostics). Membranes were prepared
and solubilized in buffer composed of 20 mM Tris (pH 7.4),
150 mM NaCl, 3 mM EDTA, and 1% Nonidet P-40. The recep-
tor was immunoprecipitated with the anti-M3-muscarinic
receptor monoclonal antibody. Immune complexes were
washed three times in solubilization buffer and resuspended
in 2 SDS-PAGE sample buffer. Receptors were separated by
SDS-PAGE on 8% gels, transferred on to nitrocellulose mem-
branes, and immunoblotted with anti-phosphoserine 384,
anti-phosphoserine 412, or anti-phosphoserine 577 antibod-
ies. For the detection of total receptors, membranes were
stripped and re-probed with an anti-mouse M3 muscarinic
receptor antibody. Western blots were digitized and quanti-
fied as described above.
Total [3H]Inositol Phosphate Accumulation Assay—To as-
sess agonist efficacy, total [3H]inositol phosphate accumula-
tion assay was carried out CHO-m3 cells. In brief, cells seeded
at 100,000 cells/well in 24-well plates were labeled with 2.5
Ci/mlmyo-[3H]inositol (PerkinElmer Life Sciences) for 24 h
at 37 °C. Cells were washed twice in Krebs/HEPES buffer (pH
7.4) and incubated with 10 mM LiCl for 20 min at 37 °C. Ap-
propriate concentrations of agonist were added for 10 min to
stimulate [3H]inositol phosphate production. Reactions were
terminated by rapid aspiration of the buffer and addition of 1
M ice-cold trichloroacetic acid (500 l). Cell lysates were
transferred to centrifuge tubes and incubated with 10 mM
EDTA (50 l) and 1,1,2-trichlorofluoroethane/tri-n-octyl-
amine (1:1, v/v, 500 l) for 15 min at room temperature. Sam-
ples were centrifuged at 20,000 g for 4 min. An400-l
aliquot from the top layer was recovered and transferred to
fresh tubes containing 60 mM NaHCO3. [3H]Inositol mono-,
bis-, and trisphosphate ([3H]InsPx) fraction was recovered by
anion exchange chromatography as follows: Dowex-1 (for-
mate form) columns were regenerated with 10 ml of ammo-
nium formate (2 M), formic acid (0.1 M) and washed thor-
oughly with distilled water. Samples were applied to the
columns, and the columns washed with 10 ml of distilled wa-
ter. Columns were then washed with ammonium formate (60
mM), sodium tetraborate (10 mM) solution. Total [3H]InsPx
was eluted in 10 ml of ammonium formate (0.75 M), formic
acid (0.1 M) and collected in large scintillation vials. A 5-ml
aliquot from the eluate was mixed with 10 ml of SafeFluor
scintillation mixture, and radioactivity was detected by liquid
scintillation counting.
Muscarinic Receptor Expression Levels—The expression
levels of the M3-muscarinic receptor were determined in
membranes isolated from the hippocampus, cortex, and sub-
mandibular salivary gland by subtracting the specific binding
of the muscarinic antagonist N-[3H]methylscopolamine ob-
tained from wild-type mice from that obtained fromM3-mus-
carinic receptor knock-out mice. N-[3H]Methylscopolamine
binding was conducted as described previously (13). The M3-
muscarinic receptor expression levels in hippocampus, cortex,
and submandibular gland were 258, 351, and 335 fmol/mg
protein, respectively.
Immunocytochemistry of Salivary Submandibular Glands—
The submandibular glands from wild-type mice or M3-mus-
carinic receptor gene knock-out mice were dissected and
fixed in 10% neutral buffered formalin. The fixed tissue were
embedded in paraffin and processed on a Shandon Citadel
2000 where serial sections (5 m) were cut. Sections where
dewaxed in xylene, dehydrated through alcohol, and then
washed with distilled water. The sections were then treated
for microwave antigen retrieval in a Sanyo Shower Wave
1000-watt microwave, at 700 watts for 20 min in a 0.01 M cit-
rate buffer (pH 6.0). Sections were then permeabilized with
Triton X-100, and the M3-muscarinic receptor was stained
with either anti-M3 muscarinic receptor antibodies or recep-
tor phospho-specific antibodies used at a dilution of 1:200
using methods described previously (5, 14).
Data Analysis—Data presented are means S.E. of at least
three determinations, and statistically significance differences
were determined using analysis of variance followed by the
Bonferroni post test. Significance was accepted at p 0.05.
RESULTS
Phosphorylation Profile of the M3-muscarinic Receptor in
Three Cell Types—The phosphorylation profile of the
mouse M3-muscarinic receptor expressed in Chinese ham-
ster ovary (CHO) cells as a recombinant protein or as an
endogenously expressed protein in the mouse insulinoma
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cell line, MIN6, and mouse primary CG neurons was investi-
gated. The receptor was immunoprecipitated from
[32P]orthophosphate-labeled cells and digested with trypsin.
The tryptic phosphopeptides were then resolved by two-di-
mensional chromatography, and an autoradiograph was ob-
tained to provide a phosphopeptide map (Fig. 1A).
The phosphopeptide map from the three cell types revealed
a quartet of phosphopeptides labeled 1–4 that served to ori-
ent the map (Fig. 1B). These peptides were seen in all three
cell types as were phosphopeptides labeled A and X (Fig. 1B).
In contrast, there were a number of phosphopeptides that
were observed in only one of the three cell types. Thus, phos-
phopeptides labeled with three asterisks were only observed
in receptors derived from CHO cells (Fig. 1B). Four phospho-
peptides labeled with two asterisks were only observed in CG
neurons, and the phosphopeptide labeled with two plus signs
was only observed in insulinoma cells. There were some phos-
phopeptides that were shared just between two cell types as
illustrated by phosphopeptides Y and B that are shared be-
tween CHO cells and CG neurons.
These studies demonstrated that although there were com-
mon features in the phosphorylation profiles of the M3-mus-
carinic receptor in the three cell types investigated, there were
also specific differences that make the overall phosphoryla-
tion profile of the M3-muscarinic receptor expressed in each
of the cell types unique.
Mass Spectrometry Identification of Phospho-acceptor Sites
and Generation of Phospho-specific Antibodies—Although the
phosphopeptide maps described above illustrate differential
receptor phosphorylation, these studies do not reveal the pre-
cise sites of phosphorylation. To do this, we conducted a mass
spectrometric analysis of the phospho-acceptor sites on the
M3-muscarinic receptor expressed in CHO cells. These stud-
ies revealed 13 serine and 2 threonine phospho-acceptor sites
in the third intracellular loop and one serine (Ser577) in the
C-terminal tail (Fig. 2).
FIGURE 1.Differential phosphorylation of the M3-muscarinic receptor in CHO cells, MIN6 insulinoma cells, and CG neurons. A, schematic of the
method employed in generating a tryptic phosphopeptide map. Step 1, cells are labeled with [32P]orthophosphate and stimulated with agonist for 5 min.
The cells are then lysed and the receptors immunoprecipitated and resolved by SDS-PAGE. An autoradiograph of the gel determines the position of the
radiolabeled receptor, which is excised from the gel. Step 2, excised gel band is tryptically digested. Step 3, tryptic digest is spotted onto a cellulose plate
and subjected to electrophoresis and ascending chromatography to resolve the tryptic peptides. The position of the phosphopeptides is determined by
exposing the gel in a phosphorimager. B, tryptic phosphopeptide maps of the mouse M3-muscarinic receptor immunoprecipitated from CHO-m3 (CHO), CG
neurons, and MIN6 insulinoma cells. For ease of viewing, the autoradiographs are divided into three sections denoted by the boxes. Phosphopeptide
“spots” are labeled to designate spots that are unique to a cell type or shared between cell types (see key on the figure). Each autoradiograph is representa-
tive of at least three independent experiments.
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Phospho-specific antibodies were raised to phosphorylated
Ser384 and Ser412 in the third intracellular loop and Ser577 in
the C-terminal tail. These were chosen because they repre-
sented phosphorylated residues that were not within a cluster
of phosphorylation sites (which would have made specific
antibody generation difficult) and that were sites determined
to have high antigenicity. The antiserum from each of the
immunizations was subjected to affinity purification that sep-
arated nonphospho-specific antibodies (structural antibodies)
and phospho-specific antibodies. To test the specificity of the
purified antiserum, the nonphosphorylated epitopes present
in bacterial glutathione S-transferase (GST) fusion proteins
containing either the third intracellular loop of the receptor
or the C-terminal tail were probed in Western blots with the
structural antibody and the phospho-specific receptor anti-
bodies (Fig. 3, A–C). In these experiment, the structural anti-
FIGURE 2.Determination of the sites of phosphorylation on theM3-muscarinic receptor bymass spectrometry. A, recombinant mouse M3-muscarinic
receptor expressed in CHO cells was stimulated with methacholine (100 M) for 5 min. Membranes were then prepared, and the receptor was purified. The
receptor was subjected to tryptic digestion, and the peptides were analyzed by mass spectrometry. Shown is a schematic indicating the phospho-acceptor
sites in the third intracellular loop and C-terminal tail. Also shown are typical LC-MS/MS traces that identify serines 384, 412, and 577 as phosphoserines.
B, list of the phosphopeptides identified by LC-MS/MS. The phosphorylated residue is highlighted in red. Note that where residues are labeled with an aster-
isk, it was not possible to determine which of the residues were phosphorylated. All the peptides shown were observed in at least two independent experi-
ments. C, schematic of the full amino acid sequence of the mouse M3-muscarinic receptor indicating the position of the phosphorylated residues in red and
underlined.
FIGURE 3. Characterization of phospho-specific antibodies raised against serines 384, 412, and 577. Crude bacterial lysates containing either GST or
GST fused to the third intracellular loop of the mouse M3-muscarinic receptor (3i-loop) or C-terminal tail (C-tail) were probed with the following antibodies.
A, antibodies against GST. This served as a loading control as did the Coomassie stain of gel. B, nonphospho-specific antibodies (structural) generated from
the immunization. C, purified phospho-specific antibodies. D, CHO cells expressing the recombinant mouse M3-muscarinic receptor were stimulated with
methacholine (100 M) for 5 min. The receptor was then solubilized and immunoprecipitated with an M3-muscarinic receptor specific monoclonal anti-
body. The nitrocellulose was then probed with the phospho-specific antibodies to serines 384, 412, and 577. Where indicated the immunoprecipitated re-
ceptor was treated with calf intestinal phosphatase (CIAP) to remove phosphates from the receptor. The sample was also probed with an antibody against
the M3-muscarinic receptor (anti-M3-receptor) as a loading control. The data shown are representative of at least two experiments.
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bodies reacted with the appropriate fusion protein. The phos-
pho-specific antibody fraction did not recognize the GST
fusion proteins (Fig. 3, B and C). The phospho-specific anti-
bodies did, however, identify the intact M3-muscarinic recep-
tor immunoprecipitated from transfected CHO cells (Fig. 3D).
This immunoreactivity was lost following de-phosphorylation
with calf intestinal phosphatase (Fig. 3D).
Determination of Cell Type-specific M3-muscarinic Receptor
Phosphorylation Using Receptor Phospho-specific Antibodies—
The phosphorylation status of the M3-muscarinic receptor at
residues 384, 412, and 577 was investigated on receptors ex-
pressed in CHO cells, CG neurons, and MIN6 insulinoma
cells (Fig. 4). Receptors derived from CHO cells showed high
basal levels of phosphorylation on Ser384 that fell by 82% fol-
FIGURE 4. Phospho-specific antibodies reveal differential phosphorylation of the M3-muscarinic receptor. A, either nontransfected CHO cells (NT) or
CHO cells expressing the mouse M3-muscarinic receptor (CHO-m3) were stimulated with or without methacholine (Meth) for 5 min. The cells were then
lysed, and the lysate was probed in a Western blot with receptor phospho-specific antibodies. Shown also is a loading control probed for tubulin. Graphs
representing quantification of the blots are shown below the autoradiographs. B,MIN6 insulinoma cells and primary cultures of CG neurons derived from
wild-type mice (WT) or mice where the M3-muscarinic receptor was knocked out (KO) were processed as described in A above. As a loading control, the ly-
sate was probed for total M3-muscarinic receptor content (anti-M3-receptor). Shown are representative blots and below each blot graphical quantification.
Graphs present the means S.E. of three independent experiments. *, p 0.05 (t test).
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lowing receptor stimulation with the full agonist methacho-
line. In contrast, agonist stimulation increased phosphoryla-
tion on Ser384 by 28% in receptors expressed in CG neurons
(Fig. 4A). In MIN6 cells, the receptor was basally phosphory-
lated on Ser384 and was not changed following agonist stimu-
lation (Fig. 4B). These data demonstrate that phosphorylation
at Ser384 was regulated differentially in the three cell types.
Analysis of the phosphorylation status of the receptor at
Ser577 also showed the importance of cell background. In
CHO cells and CG neurons, Ser577 phosphorylation was in-
creased following agonist stimulation by 61 and 50%, respec-
tively (Fig. 4, A and B). Interestingly there was no evidence of
basal or agonist-mediated phosphorylation at Ser577 from re-
ceptors expressed in MIN6 cells (Fig. 4B).
Similarly, there was clear agonist-mediated phosphoryla-
tion at Ser412 from receptors derived from CHO cells and
CG neurons. However, there was no evidence for Ser412
phosphorylation on receptors expressed in MIN6 cells (Fig.
4, A and B).
Analysis of in VivoM3-muscarinic Receptor Phosphorylation—
To evaluate differential phosphorylation of the M3-musca-
rinic receptor in vivo, membranes were prepared from the
hippocampus, cerebral cortex, and pancreas from either wild-
type mice or from mice where the M3-muscarinic receptor
gene had been knocked out. The membranes were then solu-
bilized; the M3-muscarinic receptor was immunoprecipitated
with a receptor-specific monoclonal antibody, and the immu-
noprecipitate was probed in Western blots with receptor
phospho-specific antibodies. In these experiments, the M3-
muscarinic receptor expressed in the hippocampus was deter-
mined to be phosphorylated equally on Ser318 and Ser412 but
was phosphorylated to a lesser extent on serine577 (Fig. 5A).
The phosphorylation profile for the receptor appeared differ-
ent in the cerebral cortex where the receptor was equally
phosphorylated on Ser318 and Ser577 but less phosphorylated
on Ser412 (Fig. 5A). The receptor showed a further unique
phosphorylation profile in the pancreas where the receptor
was generally poorly phosphorylated, showing a weak signal
for phosphorylation on Ser318 and Ser412 but no detectable
phosphorylation of Ser577 (Fig. 5A).
The molecular weight of the M3-muscarinic receptor im-
munoprecipitated from the pancreas (Fig. 5A) and from
MIN6 insulinoma cells (Fig. 4B) was observed to be greater
than that in the brain and CHO cells. The reason for this is
likely to be differential glycosylation because the receptor was
poorly phosphorylated in pancreatic cell/tissue types; hence,
phosphorylation was not likely to be a major contributory
factor in the apparently high molecular weight of the receptor
in these experiments.
We also investigated the phosphorylation status of the M3-
muscarinic receptor in salivary submandibular glands. How-
ever, we were not able to detect the receptor in Western blots
from this tissue probably because the receptor was subjected
to proteolysis. We were, however, able to detect the receptor
by immunocytochemistry where the M3-muscarinic receptor
was determined to be expressed in the excretory cells as well
as in the cells of the excretory ducts (Fig. 5B). In these experi-
ments weak staining for the receptor phosphorylated on
Ser384 and Ser412 was detected, although there was stronger
staining for phosphorylation on Ser577 (Fig. 5B).
Hence, the phosphorylation profile of the M3-muscarinic
receptor was different in each of the four tissues. This differ-
ence is illustrated as a bar code in Fig. 5C.
Differential Regulation of Phosphorylation by Different Mus-
carinic Receptor Agonists—The studies above provide evi-
dence that the phosphorylation status of the M3-muscarinic
receptor is dependent on the cell and tissue type in which the
receptor is expressed. We extended this analysis by investigat-
ing if different agonists working at the receptor expressed in
the same cell type could mediate different receptor phosphor-
ylation profiles. To this end, the phosphorylation profile of
the human M3-muscarinic receptor expressed in CHO-m3
cells following stimulation by the agonists methacholine, pilo-
carpine, and arecoline was investigated. Previous studies had
established that methacholine acts as a full agonist at musca-
rinic receptors and pilocarpine and arecoline as partial ago-
nists (15, 16).
In this study, assays of inositol phosphate accumulation
(InsPx) established methacholine as a full agonist at the M3-
muscarinic receptor and arecoline and pilocarpine as partial
agonists (Fig. 6A). Consistent with previous studies (15, 16),
the rank order of potency and maximal response (efficacy) for
the InsPx response was methacholine arecoline pilo-
carpine (Fig. 6A). In phosphorylation assays, all three agonists
stimulated an increase in total receptor phosphorylation with
the same rank order of efficacy as that observed in the InsPx
assay (Fig. 6B).
To determine the rank order of efficacy of the agonists at
individual phosphorylation sites, phosphopeptide maps were
generated following stimulation with the three agonists (Fig.
7, A–E). In these experiments, the relative intensity of four
spots (labeled 1–4, Fig. 7) on the phosphopeptide map were
compared. Spots 1 and 3 were significantly increased over
basal when cells when stimulated with methacholine (Fig. 7, B
and D). No significant changes in the phosphorylation of spot
1 or 3 were observed following stimulation with either areco-
line or pilocarpine (Fig. 7B). Interestingly, spot 2 was highly
phosphorylated in the basal state but became de-phosphory-
lated following methacholine stimulation (Fig. 7C). De-phos-
phorylation of spot 2 was also observed, but to a lesser extent,
following stimulation with arecoline (Fig. 7C). No significant
de-phosphorylation was observed in spot 2 with pilocarpine
(Fig. 7C). Hence, the changes in phosphorylation observed for
spots 1–3 more or less followed the expected rank order of
efficacy for the three agonists. This, however, was in contrast
to the phosphorylation of spot 4. Here, all three agonists in-
creased phosphorylation at spot 4 with equivalent efficacy
(Fig. 7E).
To further investigate this phenomenon, phospho-specific
antibodies to Ser384, Ser412, and Ser577 were used to probe the
effects of the three agonists on specific phosphorylation
events on the M3-muscarinic receptor in CHO-m3 cells. The
receptor showed high basal levels of Ser384 phosphorylation,
which were significantly decreased by methacholine treat-
ment (Fig. 8A). Here, arecoline and pilocarpine also decreased
phosphorylation at Ser384 with the following rank order of
Tissue-specific GPCR Phosphorylation
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efficacy: methacholine arecoline pilocarpine (Fig. 8A). A
similar decrease in the phosphorylation status of spot 2 in Fig.
7 was observed suggesting that spot 2 corresponds to the
phosphorylation site Ser384.
Ser412 phosphorylationwas relatively low in the basal state and
was increased equivalently by all three agonists (Fig. 8B). This is the
same as the effects of the three agonists on the phosphorylation sta-
tus of spot 4 in Fig. 7, suggesting that spot 4 corresponds to Ser412.
FIGURE 5.Differential phosphorylation of theM3-muscarinic receptor in the central nervous system, pancreas, and salivary glands. A,membranes
from cerebral cortex, hippocampus, and pancreas were prepared from wild-type (WT) and M3-muscarinic receptor gene knocked out (KO) mice. Membranes
were solubilized, and the M3-muscarinic receptor was immunoprecipitated using a receptor monoclonal antibody. The immunoprecipitate was probed in
Western blots with M3-muscarinic receptor phospho-specific antibodies against phosphoserine 384, 412, and 577. Shown also is a loading control probed
for total M3-muscarinic receptor (anti-M3-receptor). Data are representative of three independent experiments. B, submandibular glands from wild-type and
M3-muscarinic receptor knock-out mice were fixed in 10% formalin and processed for immunocytochemistry. Sections were stained with antibodies against
the total M3-muscarinic receptor population (anti-M3-receptor) or receptors phosphorylated on serines 384, 412, and 577. Also shown are the DAPI-stained
nuclei and the merge of the receptor staining and DAPI. C, results shown in A and B are represented as a bar code describing the relative intensities of re-
ceptor phosphorylation on serines 384, 412, and 577 in the different tissues.
Tissue-specific GPCR Phosphorylation
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Finally, phosphorylation of Ser577 was increased by all three
agonists. The rank order of efficacy was methacholine are-
coline pilocarpine.
Thus, analysis of the phosphorylation status of the M3-
muscarinic receptor with phospho-specific antibodies indi-
cated that of the phosphorylation sites investigated only ago-
nist-mediated phosphorylation at Ser577 followed the
expected rank order of efficacy (i.e.methacholine areco-
line pilocarpine). The rank order of efficacy for the changes
in phosphorylation at the other two sites (Ser384 and Ser412)
did not conform to the expected order indicating that ago-
nists were able to direct phosphorylation preferentially at
these sites.
DISCUSSION
Studies from our laboratory and from others have raised
the possibility that one mechanism by which GPCRs could
mediate cell/tissue-specific signaling may be through tissue-
specific receptor phosphorylation (4, 5, 12). To test this no-
tion, we addressed here whether a GPCR was phosphorylated
in a cell- and tissue-specific fashion. We show that the M3-
muscarinic receptor was indeed differentially phosphorylated
in CHO-m3 cells, CG neurons, and MIN6 insulinoma cells.
The capacity of this receptor subtype to be differentially phos-
phorylated was also confirmed by in vivo studies where the
M3-muscarinic receptor was found to have a unique phos-
phorylation profile in the hippocampus, cortex, pancreas, and
salivary glands. Thus, this study demonstrates that a GPCR
can be phosphorylated in a cell- and tissue-specific manner
consistent with the hypothesis that differential phosphoryla-
tion could contribute to tissue-specific receptor signaling.
Our study also highlights the complexity of GPCR phos-
phorylation with the identification of 15 phospho-acceptor
sites on the M3-muscarinic receptor. In addition, we demon-
strate the hitherto unobserved phenomenon of agonist-regu-
lated receptor de-phosphorylation. Whereas receptors are
known to be de-phosphorylated on withdrawal of the agonist
in a process that reactivates internalized receptors (2), the
notion that receptors might be phosphorylated in the basal
state and then dephosphorylated on agonist stimulation has
up to now not been considered. We show here that phosphor-
ylation on Ser384 in CHO-m3 cells was decreased following
agonist addition. Similarly, we show that a spot identified as
spot 2 in the phosphopeptide map in CHO-m3 cells was de-
creased following methacholine stimulation. We are currently
testing if spot 2 in the phosphopeptide map represents the
same phospho-acceptor site as Ser384. Importantly, this de-
phosphorylation event is cell type-specific being restricted to
receptors expressed in CHO-m3 cells. In neurons, Ser384
phosphorylation was seen to increase on agonist stimulation,
and in MIN6 cells basal phosphorylation of Ser384 remains
unchanged following agonist stimulation. Hence, the example
of Ser384 reveals the true complexity and flexibility of GPCR
FIGURE 6.Methacholine-, arecoline-, and pilocarpine-mediated inositol phosphate and receptor phosphorylation response. A, concentration-re-
sponse curve for methacholine (Mch), arecoline (Arec), and pilocarpine (Pilo) in the inositol phosphate response in CHO-m3 cells. B, phosphorylation of the
M3-muscarinic receptor in CHO-m3 cells labeled with [
32P]orthophosphate in response to muscarinic receptor agonists. C, quantification of the phosphory-
lation data presented in B. Graphs represent the means S.E. of three independent experiments. *, p 0.05; **, p 0.01; ***, p 0.001 (t test).
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phosphorylation where a site can remain unchanged or can
increase or decrease in its phosphorylation status following
agonist stimulation depending on the cell type in which the
receptor is expressed.
Are the different patterns of receptor phosphorylation
identified here likely to lead to different receptor signaling
outcomes? Whereas this is difficult to test in vivo, this has
been extensively examined in in vitro systems. Hence, studies
on the 2-adrenergic receptor have determined that the kinet-
ics of the recruitment of arrestin to the receptor was shown to
be dependent on which of the GRKs was employed in recep-
tor phosphorylation (7). That this may impact on signaling
was indicated in studies on the CCR7 chemokine receptor
where GRK6-mediated phosphorylation leads to ERK1/2 acti-
vation, but GRK3 and GRK6 had to be employed in concert to
drive receptor internalization and desensitization (12). That
members of the GRK family can actually phosphorylate differ-
ent sites on the same receptor and that these regulate differ-
ent signaling outcomes have recently been demonstrated for
another chemokine receptor CXCR4 (6).
In terms of the M3-muscarinic receptor, we and others
have determined that this receptor subtype is phosphorylated
by multiple receptor kinases, including the GRKs, protein ki-
nase CK2, and CK1 (5, 8, 17, 18). It appears that these dis-
tinct protein kinases are able to phosphorylate different sites
on the receptor and that this results in different functional
outcomes (5). Hence, phosphorylation mediated by protein
kinase CK2 does not appear to regulate receptor internaliza-
FIGURE 7.Muscarinic ligands drive preferential receptor phosphorylation. A, tryptic phosphopeptide maps of the M3-muscarinic receptor expressed in
CHO-m3 cells stimulated with a saturating concentration (100 M) of methacholine (Mch), arecoline (Arec), or pilocarpine (Pilo). Labeled are four spots (1–4),
which were compared in intensity with the reference spot marked with an asterisk. B–E, quantification of spots labeled 1–4 in relation to the reference spot.
Shown are typical autoradiographs and the cumulative mean data S.E. (n 3). *, p 0.05; **, p 0.01 (t test).
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tion nor ERK1/2 activity but rather it regulates the coupling of
the receptor to the JUN kinase pathway (5). In contrast, cou-
pling to the ERK1/2 pathway and phosphoinositide signaling
is regulated by CK1-mediated receptor phosphorylation (8,
9), and receptor desensitization and internalization are regu-
lated by the GRKs (17, 19). Thus, these findings on the M3-
muscarinic receptor, coupled to those from other GPCRs,
provide compelling evidence that the signaling outcome of
GPCRs can be determined by the sites on the receptor that
are phosphorylated.
This realization has led to the notion that the pattern of
phosphorylation of a receptor can be likened to a bar code
that encodes a particular signaling outcome that could be em-
ployed in a tissue-specific manner to fine-tune the signaling
outcome of a receptor to match a particular physiological role
(3, 10–12). Such a concept was first proposed to account for
the different signaling outcomes mediated by various mem-
bers of the GRK family on the angiotensin II receptor and V2
vasopressin receptor (10, 11). If this notion were correct, then
GPCRs would be expected to show cell/tissue-specific phos-
phorylation. Hence, the data presented here describing differ-
ent phosphorylation profiles of a GPCR in different cell/tissue
types support the notion of a phosphorylation bar code (Fig.
5C) being employed to drive tissue-specific receptor signaling.
It is therefore likely that at any given point a single receptor
molecule will display a specific pattern of phosphorylation
that is binary in a manner analogous to a bar code. It should
be noted, however, that not all of the receptors in a tissue will
necessary have the same phosphorylation bar code. Thus, a
population of receptors will reflect the average phosphoryla-
tion profile and as such will show different intensities at spe-
cific sites.
The phosphorylation bar code adopted by a receptor will be
a reflection of the receptor conformation following agonist
occupation (see below) but also the complement of protein
kinases and phosphatases employed. We know that the M3-
muscarinic receptor can be phosphorylated by a range of pro-
tein kinases, including GRK2, GRK6, CK1, and protein ki-
nase CK2 (5, 8, 17, 18). It is possible that these kinases are
employed differentially to mediate tissue-specific phosphory-
lation (3).
We extended our studies further by asking if different li-
gands could mediate different patterns of phosphorylation.
This study was conducted in the knowledge that there is a
growing list of receptor ligands that are able to direct signal-
ing of receptors preferentially to one signaling pathway over
another (20). This phenomenon has been variously described
as ligand-directed trafficking, ligand bias, and functional se-
lectivity (21–23). The importance of this for the physiological
FIGURE 8. Phospho-specific antibodies reveal the capacity of ligands to
drive preferential M3-muscarinic receptor phosphorylation. CHO-m3
cells were stimulated with a saturating concentration (100 M) of metha-
choline (Mch), arecoline (Arec), or pilocarpine (Pilo). The cells were then
lysed, and the receptor was immunoprecipitated with a receptor monoclo-
nal antibody. The immunoprecipitate was then probed with receptor phos-
pho-specific antibodies against phosphoserine 384 (A), phosphoserine 412
(B), and phosphoserine 577 (C). Shown are typical autoradiographs and the
cumulative mean data S.E. (n 3). *, p 0.05; ***, p 0.001 (t test).
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role of the M3-muscarinic receptor has recently been high-
lighted in studies from our laboratory that have determined
that the mechanism by which this receptor subtype regulates
hippocampus-basedmemory and learning is via signaling
through a receptor phosphorylation/arrestin-dependent pathway
in preference to signaling via heterotrimeric G-proteins (13).
We show here that the efficacy of three muscarinic ligands,
methacholine (full agonist), arecoline (partial agonist), and
pilocarpine (partial agonist), in mediating overall receptor
phosphorylation correlated with the efficacy of these ligands
in the activation of inositol phosphate signaling. Similar cor-
relations have been made for agonists at the 2-adrenergic
receptor where phosphorylation was measured in relation to
the maximal response of a series of full and partial agonists
(24). In this study, this correlation was not, however, main-
tained if individual sites of phosphorylation were measured
either in phosphopeptide maps or by use of phospho-specific
antibodies. Hence, agonist-mediated phosphorylation of spot
4 in the phosphopeptide map in Fig. 7 and phosphorylation at
Ser412 (Fig. 8) showed that all three agonists were full agonists
in stimulating an increase in phosphorylation at these sites.
Hence, the break from the expected rank order of efficacy
observed for Ser412 and spot 4 indicates that the impact that
the ligands have on phosphorylation is not equivalent for all
sites. That this is the case is further supported by studies on
the CXCR4 and somatostatin receptor where agonists have
been identified that are able to regulate receptor phosphoryla-
tion differently (6). Thus, the data from this study raise the
possibility that ligands can preferentially direct receptor phos-
phorylation. This being the case, it would seem plausible that
ligands that show a bias toward arrestin/phosphorylation sig-
naling may do so because they have the quality of driving
preferential phosphorylation of receptors in a manner that
promotes signaling through this pathway in preference to sig-
naling through other pathways.
In conclusion, our study supports the hypothesis that one
mechanism that is employed by biased ligands to direct recep-
tor signaling is the capacity of ligands to preferentially drive
receptor phosphorylation. Furthermore, the data presented
here also highlight the fact that GPCRs can be phosphorylated
in a cell and tissue type-specific fashion in a manner that
would provide a mechanism for cell/tissue-specific receptor
signaling.
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